Project Grant R21CA297425
Award Date 4/3/26
Completion Date 3/31/28
Dollars Obligated $474K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Grant Award Summary The Wistar Institute of Anatomy and Biology received a $780,764 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on April 15, 2026, with completion expected by March 31, 2031. This grant funds research investigating branched-chain amino acid (BCAA) oxidation and signaling pathways in tumor-associated macrophages (TAMs) to enhance anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC). The...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $483,343.83 to the University of New Mexico Health Sciences Center on May 7, 2025, under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on the regulation of ovarian cancer metastasis. The research project, which extends through November 30, 2030, investigates how microenvironmental signals activate the transcription factor C-JUN in ovarian cancer cells and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Institute For Cancer Research a Project Grant of $766,439 under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period April 1, 2026 through March 31, 2031. This research project focuses on intratumor heterogeneity as a correlate of clinical outcomes in bladder cancer patients pursuing cystectomy avoidance strategies. The primary deliverables include: (1) scientific investigation into the genetic...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This research initiative addresses immune resistance mechanisms in colorectal cancer (CRC), specifically targeting the myeloid-stromal axis that suppresses anti-tumor immunity in microsatellite stable cases resistant to immune checkpoint blockade. The research...
- The Institute For Cancer Research, a non-profit research organization and subsidiary of Temple University, was awarded a $534,445 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer, with a project period from August 1, 2023 to July 31, 2026. The Institute For Cancer Research has extensive...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University's Health Sciences Division a $683,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research on tumor-penetrating stromal modification of pancreatic ductal adenocarcinoma (PDAC) through investigation of the αvβ5 integrin pathway. The project focuses on developing and evaluating the IRGD tumor-penetrating peptide as...